Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA

BACKGROUND: We assessed the efficacy of the licensed mepolizumab dose (100 mg subcutaneously [SC]) in patients with severe eosinophilic asthma according to body weight/body mass index (BMI). METHODS: This was a post hoc individual patient-level meta-analysis of data from the Phase 3 studies MENSA (M...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Respir Res
Hlavní autoři: Albers, Frank C., Papi, Alberto, Taillé, Camille, Bratton, Daniel J., Bradford, Eric S., Yancey, Steven W., Kwon, Namhee
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6664536/
https://ncbi.nlm.nih.gov/pubmed/31362741
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-019-1134-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky